 - Phase I: Patients undergo leukapheresis for collection of peripheral blood mononuclear cells PBMC. PBMC are cultured with sargramostim GM-CSF and interleukin-4 to generate dendritic cells DCs on day -9. DCs are pulsed separately with HLA-A1 and HLA-A2.1-restricted flu matrix peptides derived from melanoma-associated tumor antigens MAGE-10.A2, Melan-A, MAGE-3, NY-ESO-1, gp100 antigen, and tyrosinase peptide. Half of the DCs are treated ex vivo with CD40-ligand. Patients receive the peptide-pulsed DC vaccinations subcutaneously SC on days 1, 14, 42, and 70 in the absence of disease progression. 